ÂÜÀòÂÒÂ×

William Slichenmyer is a highly experienced Oncology Drug Development Consultant and Partner at Alacrita Consulting since January 2015, specializing in clinical drug development and regulatory strategy. Prior roles include serving as Chief Medical Officer at AVEO Oncology and Merrimack Pharmaceuticals, along with a notable tenure at Pfizer, where responsibilities included overseeing a large regulatory team and leading global oncology clinical development efforts. Slichenmyer's previous positions also encompass senior leadership roles in pharmaceuticals, clinical research, and oncology at companies such as Parke-Davis, Hybridon, and Bristol-Myers Squibb. Slichenmyer holds a Doctor of Medicine from Case Western Reserve University and a Master of Science in Clinical Investigation from The Johns Hopkins University.